共 81 条
[1]
González-López E(2015)Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction Eur Heart J 36 2585-2594
[2]
Gallego-Delgado M(2016)Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness Eur Heart J 37 1826-1834
[3]
Guzzo-Merello G(2016)Nonbiopsy diagnosis of cardiac transthyretin amyloidosis Circulation 133 2404-2412
[4]
Damy T(2016)Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system J Am Coll Cardiol 68 1014-1020
[5]
Costes B(2012)New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes J Clin Oncol 30 4541-4549
[6]
Hagège AA(2012)Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements J Clin Oncol 30 989-995
[7]
Gillmore JD(2013)A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis Blood 121 3420-3427
[8]
Maurer MS(2020)Management of AL amyloidosis in 2020 Blood 136 2620-2627
[9]
Falk RH(2019)Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis Circ Hear Fail 12 1-11
[10]
Grogan M(2019)ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—Evidence base and standardized methods of imaging J Card Fail 25 e1-e39